Advertisement

Interferone pp 137-155 | Cite as

Immunmodulation durch Interferone — Relevanz für die Klinik?

  • M. Micksche

Zusammenfassung

Interferone (IFN) haben als körpereigene Stoffe eine pleiotrope Wirkung auf eine Vielzahl von Regulationssystemen, die sowohl Normalzellen - vorwiegend hematopoetisches System - als auch Tumorzellen betreffen [1]. IFN kann in allen kernhaltigen Zellen des Säugetierorganismus durch verschiedenste Agentien (Antigene, Induktoren), Mikroorganismen bzw. Viren induziert werden [2]. IFN werden entsprechend der WHO-Klassifikation in Typ α (Leukozyten-IFN), ß (Fibroblasten-IFN) und in γ (Immun- oder T-Lymphozyten-IFN) eingeteilt. Sie unterscheiden sich sowohl aufgrund der Struktur und Aminosäuresequenz, als auch in ihrer biologischen Aktivität.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    (1971) Interferon. Virology Monograph No. 6, Wien and New York, Springer VerlagGoogle Scholar
  2. 2.
    Finter NB (1973) Interferon and Interferon Inducers. Amsterdam, North HollandGoogle Scholar
  3. 3.
    Mizraki A, Reuveny S, Traub A, Minai M (1980) Large scale production of human lymphoblastoid interferon. Biotechnol Lett 2: 267–271Google Scholar
  4. 4.
    Streuli M, Nagata S, Weissmann C (1980) At least three human type alpha-interferons. Science 209: 1343–1347PubMedCrossRefGoogle Scholar
  5. 5.
    Goeddel DV, Yelvertan E, Ullrich A et al (1980) Human leukocyte interferon produced by E. coli is biologically active. Nature 287: 411–416PubMedCrossRefGoogle Scholar
  6. 6.
    Pohl A, Moser K, Micksche M (1981) Humane Interferone - Eigenschaften und Möglichkeiten. Wr Klin Wschr 93: 439–457Google Scholar
  7. 7.
    Bradley EC, Ruscetti FW (1982) Effect of fibroblast, lymphoid and myeloid interferons on human tumor colony formation in vitro. Cancer Res 41: 244–249Google Scholar
  8. 8.
    Balkwill FR, Aldam G, Lee A (1985) The action of interferons on human tumor xeno-grafts growing in nude mice. In: Dianzani F, Rossi GB (eds) The Interferon system. Raven Press, New York, pp 327–331Google Scholar
  9. 9.
    Rossi GB (1985) Interferons and cell differentiation. In: Gresser I. (ed) Interferon 6. Academic Press, London, pp 31–50Google Scholar
  10. 10.
    Clemens MJ, McNurlan MA (1985) Regulation of cell proliferation and differentiation by interferons. Biochem J 226: 345–360PubMedGoogle Scholar
  11. 11.
    Hicks NJ, Morris AG, Burke DC (1981) Partial reversion of the transformed phenotype of murine sarcoma virus transformed cells in the presence of interferon: a possible mechanism for the anti-tumor effect of interferon. J Cell Sei 49: 225–226Google Scholar
  12. 12.
    Clemens M (1985) Interferons and oncogenes. Nature 313: 531–532PubMedCrossRefGoogle Scholar
  13. 13.
    Biological response Modifiers (1983) Subcommittee Report. NCI Monograph Nr. 63Google Scholar
  14. 14.
    Micksche M, Colot M, Uchida A (1984) Modulation of human lymphocytotoxicity by biological response modifiers. In: Fenichel RL, Chinigas MA (eds) Immunomodulating Agents: Properties and Mechanisms. Marcel Dekker Inc., New York, pp 363–379Google Scholar
  15. 15.
    Gresser I, Mavrey C, Brovty-Boye D (1979) Mechanism of the antitumor effects of interferon in mice. Nature 239: 167–168CrossRefGoogle Scholar
  16. 16.
    Ernstoff MS, Fusi S, Kirkwood JM (1983) Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon ( IFN-a) phase I-II trials. J Biol Response Mod 2: 528–539Google Scholar
  17. 17.
    Herbermann RB, Thurman GB (1983) Approaches to the immunological monitoring of cancer patients treated with natural or recombinant interferons. J Biol Resp Modf 2: 548–562Google Scholar
  18. 18.
    Branca A, Baglioni C (1981) Evidence that types I and II interferons have different receptors. Nature 294: 768PubMedCrossRefGoogle Scholar
  19. 19.
    Zinkernagel RM, Doherty PC (1974) Immunological surveillance against altered self components by sensitized T lymphocytes in lymphocytic choriomeningitis. Nature 251: 547–548PubMedCrossRefGoogle Scholar
  20. 20.
    Herbermann RB (ed) (1982) NK cells and other natural effector cells. Academic Press, New YorkGoogle Scholar
  21. 21.
    Zarling JM, Sosman J, Eskra A et al (1978) Enhancement of T cell cytotoxic response by purified human fibroblast interferon. J Immunol 121: 2002–2004PubMedGoogle Scholar
  22. 22.
    Farrar WL, Joanson HM, Farrar JJ (1981) Regulation of the production of immune interferon and cytotoxic T-lymphocytes by interleukin 2. J Immunol 126: 1120–1125PubMedGoogle Scholar
  23. 23.
    Imai KA, Ng K, Glassy MC, Ferrone S (1981) Differential effect of interferon on the expression of tumor-associated antigens and histocompatibility antigens on human melannoma cells: relationship to susceptibility to immune lysis mediated by monoclonal antibodies. J Immunol 127: 505–508PubMedGoogle Scholar
  24. 24.
    Thomas HC, Seelly LJ (1985) Antiviral therapy in hepatitis B infection. Brit Med Bulletin 41: 374–380Google Scholar
  25. 25.
    Lindahl P, Leary P, Gresser I (1972) Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Acad Sci USA 69: 721–725PubMedCrossRefGoogle Scholar
  26. 26.
    Heron I, Berg K, Cantell K (1976) Regulatory effect of interferon on T cells in vivo. J Immunol 117: 637Google Scholar
  27. 27.
    Herberman RB (ed) (1980) Natural cell-mediated immunity against tumors. Academic Press, New YorkGoogle Scholar
  28. 28.
    Gorelik E, Wilhout RH, Okumura K et al (1982) Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int J Cancer 30: 107–112PubMedCrossRefGoogle Scholar
  29. 29.
    Lotzova E, McCredie KB (1978) Natural killer cells in mice and man and their biological significance. Cancer Immunol Immunother 4: 215–221CrossRefGoogle Scholar
  30. 30.
    Djeu JY, Timonen T, Herberman RB (1982) Production f interferon by human natural killer cells in response to mitogens, viruses and bacteria. In: Herberman RB (ed) NK Cells and Other Natural Effektor Cells. Academic Press, New YorkGoogle Scholar
  31. 31.
    Sibbit W Jr, Bankhurst AD, Jumonville AJ et al (1984) Defect in natural killer cell activity and interferon response in human lung carcinoma and malignant melanoma. Cancer Res 44: 552–556Google Scholar
  32. 32.
    Cunningham-Rundles S, Filippa DA, Braun DW Jr, et al (1981) Natural cytotoxicity of peripheral blood lymphocytes and regional lymph node cells in breast cancer women. JCNI 67: 585–590Google Scholar
  33. 33.
    Vose BM, Gallagher P, Moore M, et al (1981) Specific and non-specific lymphocyte cytotoxicity in colon carcinoma. Brit J Cancer 44: 846–855PubMedCrossRefGoogle Scholar
  34. 34.
    Uchida A, Micksche M (1981) Natural killer cells in carcinomatous pleural effusions. Cancer Immunol Immunother 11: 131–138Google Scholar
  35. 35.
    Uchida A, Micksche M (1983) Lysis of fresh tumor cells by autologous large granular lymphocytes from peripheral blood and pleural effusions. Int J Cancer 32: 37–44PubMedCrossRefGoogle Scholar
  36. 36.
    Targan S, Rorey F (1980) Interferon activation of “prespontaneous” killer (pre-NK) cells and alterations in kinetics of lysis of both “pre-NK” and active NK cells. J Immunol 124: 2157–2162PubMedGoogle Scholar
  37. 37.
    Ortaldo JR, Pestka S, Slease RB, et al (1980) Augmentation of human NK-cell activity with interferon. Scand J Immunol 12: 365–369PubMedCrossRefGoogle Scholar
  38. 38.
    Antonelli P, Stewart W II, Dupont B (1981) Distribution of natural killer cell activity in peripheral blood, cord clood, thymus, lymph nodes and spleen, and the effect of in vitro treatment with interferon preparations. Clin Immunol Immunopathol 19: 168–172CrossRefGoogle Scholar
  39. 39.
    Huddlestone JR, Merigan TC Jr, Oldstone MB (1979) Induction and kinetics of natural killer cells in humans following interferon therapy. Nature 282: 417–420PubMedCrossRefGoogle Scholar
  40. 40.
    Golub SH, Dorey F, Hara D, et al (1982) Systemic administration of human leukocyte interferon to melanoma patients. I. Effects of natural killer function and cell populations. J Nat Cancer Inst 16: 703Google Scholar
  41. 41.
    Edwards BS, Merrit JA, Fuhibrigge RC, et al (1983) Low doses of interferon alpha result in more effective clinical natural killer cell activation. J Clin Invest 74: 1908Google Scholar
  42. 42.
    Kuzmits R, Kokoschka EM, Micksche M, et al (1985) Phase II results with recombinant interferons: Renal cell cancer and malignant melanoma. Oncology 42/Supp 1: 26–32PubMedCrossRefGoogle Scholar
  43. 43.
    Lenzhofer R, Micksche M, Dittrich CH, et al (1984) Recombinant human IFN-alpha (RHU-IFN-ALPHA-2) in advanced breast cancer. Drugs under experimental and clinical research X (7) 463–470Google Scholar
  44. 44.
    Ludwig H, Linkesch W, Gisslinger H, et al (1987) Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders. Cancer Immunol Immunother 25: 266–273PubMedCrossRefGoogle Scholar
  45. 45.
    Schwarzmeier JD, Wagner L, Prischl F, et al (1987) Rekombinante (IFN-a2b)-Therapie der Haarzell-Leukämie. Klin Wschr 65: 699–705PubMedCrossRefGoogle Scholar
  46. 46.
    Maluish AE, Ortaldo JR, Conlon JC, et al (1983) Depression of natural killer cytotoxicity after the in vivo administration of recombinant leukocyte interferon. J Immunol 131: 505–509Google Scholar
  47. 47.
    Uchida A, Colot M, Micksche M (1984) Suppression of natural killer cell activity by adherent effusion cells of cancer patients. Suppression of motility binding capacity and lethal hit of NK cells. Brit J Cancer 49: 17–23Google Scholar
  48. 48.
    Uchida A, Yanagawa E, Micksche M, et al (1984) In vitro modulation of human natural cytotoxicity by interferon and generation of adherent suppressor cells. Brit J Cancer 50: 483–492PubMedCrossRefGoogle Scholar
  49. 49.
    Pattengale PK, Sundstrom C, Yu AL, et al (1983) Lysis of fresh leukemic blast by interferon-activated human natural killer cells. Nat Immun Cell Growth Regul 3: 165PubMedGoogle Scholar
  50. 50.
    Berek JS, Hacker NF, Lichtenstein A, et al (1985) Intraperitoneal recombinant A-Interferon for “Salvage” Immunotherapie in stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. Cancer Res 45: 4447Google Scholar
  51. 51.
    Kurzrock R, Rosenblum MB, Sherwin SA, et al (1985) Pharmakokinetics, single dose tolerance and biological activities of recombinant gamma-interferon in cancer patients. Cancer Res 45: 2866–2872PubMedGoogle Scholar
  52. 52.
    Bonnern EM, Oldham RK (1987) Gamma-Interferon: Physiology and Speculation on its role in Medicine. J Biol Resp Mod 6: 275–391Google Scholar
  53. 53.
    Territo M, Sarna G, Figlin R (1983) Effect of in vivo administration of interferon on human monocyte function. J Biol Resp Mod 2: 450Google Scholar
  54. 54.
    Schieder K, Kölbl H, Nowotny CH, et al (1988) Intrakavitäre Therapie mit “biological response modifiers (BRM)” an Patientinnen mit fortgeschrittenem Ovarialkarzinom und Aszites. Submitted for publicationGoogle Scholar
  55. 55.
    Johnston RB (1988) Current concepts in Immunology: Monocytes and Macrophages. New Engl J Med 318: 747–752PubMedCrossRefGoogle Scholar
  56. 56.
    Yanagawa E, Uchida A, Micksche M (1984) Natural cytotoxicity of lymphocytes and monocytes and its augmentation by OK432 in melanoma patients. Cancer Immunol Immunother 16: 131–136PubMedCrossRefGoogle Scholar
  57. 57.
    Yanagawa E, Uchida A, Micksche M (1985) Autologous tumor killing and natural cytotoxic activity of tumor-associated macrophages in cancer patients. Cancer Immunol Immunother 19: 163–167PubMedCrossRefGoogle Scholar
  58. 58.
    Nathan CF, Prendergast TJ, Wiebe ME, et al (1984) Activation of human macrophages: comparison of other cytokines with interferon. J Exp Med 160: 600–605PubMedCrossRefGoogle Scholar
  59. 59.
    Matuish AE, Learitt R, Sherwin SA, et al (1983) Effects of recombinant interferon-a on immune function in cancer patients. J Biol Resp Mod 2: 470–481Google Scholar
  60. 60.
    Territo M, Sarna G, Figlin R (1983) Effect of in vivo administration of interferon on human monocyte function. J Biol Resp Mod 7: 450–457Google Scholar
  61. 61.
    Hengst JCD, Kempf RA, Kan Mitchell J, et al (1983) Immunological effects of recombinant interferon-a2 in cancer patients. J Biol Resp Mod 2: 516–527Google Scholar
  62. 62.
    Rinchart JJ, Young D, Laforge J, et al (1987) Phase I/II trial of recombinant gamma- interferon in patients with renal cell carcinoma: Immunologic and biologic effects. J Biol Resp Mod 6: 302–312Google Scholar
  63. 63.
    Weinstein Y, Brodeur BR, Melmon KL, et al (1977) Interferon inhibition of lymphocyte mitogenesis. Immunology 33: 313–319PubMedGoogle Scholar
  64. 64.
    Silver HKB, Connors JM, Karim KA, et al (1983) Effect of lymphoblastoid interferon on lymphocyte subsets in cancer patients. J Biol Resp Mod 2: 428Google Scholar
  65. 65.
    Karavodin LM, Golub SH (1983/84) Systemic administration of human leukocyte interferon to melanoma patients: III. Increased helper: suppressor cell ratios in melanoma patients during interferon treatment. Nat Immun Cell Growth Regul 3: 193–202Google Scholar
  66. 66.
    Mittleman A, Krown SE, Cirrincione C, et al (1983) Analysis of T cell subsets in cancer patients treated with interferon. Amer J Med 75: 966 - 972CrossRefGoogle Scholar
  67. 67.
    Ernsthoff MS, Fusi S, Kirkwood JM (1983) Parameters of interferon action. II. Immunologic effects of recombinant leukocyte interferon (IFN-a2) in phasel-II clinical trial. J Biol Resp Mod 2: 540–547Google Scholar
  68. 68.
    Talpaz M, Rosenblum M, Kurzrock R, et al (1987) Clinical and Laboratory Changes Induced by Alpha Interferon in Chronic Lymphocytic Leukemia - A Pilot Study. Amer J Hematol 24: 341–350CrossRefGoogle Scholar
  69. 69.
    Thompson JA, Welby Cox W, Lindgreen CG, et al (1987) Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects. Cancer Immunol Immunother 25: 47–53PubMedCrossRefGoogle Scholar
  70. 70.
    Onsrud M (1982) Enhancement of Suppressor Cell Generation in Human Mixed Lymphocyte Cultures by Interferon. Int Archs Allergy appl Immun 67: 315–321CrossRefGoogle Scholar
  71. 71.
    Ernsthoff MS, Gallicchio V, Kirkwood JM (1985) Analysis of granulocyte-macrophage progenitor cells in patients treated with recombinant interferon alpha-2. Amer J Med 79: 167–170CrossRefGoogle Scholar
  72. 72.
    Szigeti R, Masucci MG, Masucci G, et al (1980) Interferon suppresses antigen- and mitogen-induced leukocyte migration inhibition. Nature 288: 594–596PubMedCrossRefGoogle Scholar
  73. 73.
    Gisler RH, Lindahl P, Gresser I (1974) Effects of interferon on antibody synthesis in vitro. J Immunol 113: 438PubMedGoogle Scholar
  74. 74.
    Härfast B, Huddlestone JR, Casali P, et al (1981) Interferon acts directly on human B lymphocytes to modulate immunoglobulin synthesis. J Immunol 127: 2146–2150PubMedGoogle Scholar
  75. 75.
    Ludwig H, Coatelezzi A, Scheithauer W, et al (1986) Recombinant interferon-alfa-2c versus polychemotherapy ( VMCP) for treatment of multiple myloma: A prospective randomized trial. Eur J Cancer Clin Oncol 22: 111–116Google Scholar
  76. 76.
    Kinoyama S, Bodicky CJ, Perrillo RP, et al (1987) Immune Modulation of Peripheral Blood Mononuclear Cells ( PBMC) From Patients with Chronic Type B Hepatitis Treated With Combination Prednisone and Alpha Interferon. J Hepatology Abstr Nr 339Google Scholar
  77. 77.
    Grob PJ, Joller-Jemelka HI, Binswanger U, et al (1984) Interferon as an Adjuvant for Hepatitis B Vaccination in Non- and Low-Responder Populations. Eur J Clin Microbiol 3: 195–198PubMedCrossRefGoogle Scholar
  78. 78.
    Hersey D, Coates A, Rollings M, et al (1936) Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma. J Biol Resp Mod 5: 236–249Google Scholar
  79. 79.
    Epstein LB (1981) Interferon as a model lymphokine. Fed Proc 40: 56–61PubMedGoogle Scholar
  80. 80.
    Farrar WL, Johnson HM, Farrar J J (1981) Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin 2. J Immunol 126: 1120–1125PubMedGoogle Scholar
  81. 81.
    Yamamoto A, Nagamuta M, Usami H, Sugawara Y, Watanabe N, Niitsu Y, UrushizakiGoogle Scholar
  82. 82.
    1986) Release of tumor necrosis factor (TNF) into mouse peritoneal fluids by OK-432, a streptococcal preparation. Immunopharmacology 11:79–86Google Scholar
  83. 83.
    Mori H, Mihara M, Teshima K, Uesugi U, Xu Q, Sakamoto O, Koda A (1987) Effect of immunostimulants and antitumor agents on tumor necrosis factor ( TNF) production. Int J Immunopharmacol 9: 881–892Google Scholar
  84. 83.
    Watanabe N, Niitsu Y, Yamauchi N, et al (1988) Antitumor synergism between recombinant human tumor necrosis factor and recombinant human interferon. J Biol Resp Mod 7: 24–31Google Scholar
  85. 84.
    Editorial (1988) Neopterins in clinical medicine. Lancet i: 509–511Google Scholar
  86. 85.
    Lang A, Niederwieser D, Huber CH, et al (1985) Treatment with recombinant interferon alfa-2 induces increase of in vivo Neopterin excretion. In: Wächter H, Curtirs HC, Pfleiderer W (eds) Biochemical and clinical aspects of Pteridines. Vol. 4. Walter de Gruyter, pp 369–377Google Scholar
  87. 86.
    Wallach D, Fellows M, Revel M (1982) Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs. Nature 299: 833–836PubMedCrossRefGoogle Scholar
  88. 87.
    Vogel SN, English KE, Fertsch D, et al (1983) Differential modulation of macrophage membrane markers by interferon: analysis of Fc and C3b receptors, Mac-1 and la antigen expression. J Interferon Res 3: 153–160PubMedCrossRefGoogle Scholar
  89. 88.
    Ng AK, Imai K, Pellegrino MA, et al (1983) Modulation of immune lysis of tumor cells by interferon. Biomembrane 11: 313–339Google Scholar
  90. 89.
    Welsch RM, Ortaldo JR, Kiessling RW (1982) Modification of target susceptibility to activated mouse NK cells by interferon and virus infections. In: Herberman RB (ed) NK cells and Other Natural Effector Cells. Academic Press, New YorkGoogle Scholar
  91. 90.
    Baldini L, Cortelezzi A, Polli N, et al (1986) Human recombinant interferon alpha-2C ( INFa) enhances the expression of class II HLA antigens on hairy cells. Blood 67: 458Google Scholar
  92. 91.
    Greiner JW, Horan-Hand P, Noguchi P, et al (1984) Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte interferon treatment. Cancer Res 44: 3208–3214PubMedGoogle Scholar
  93. 92.
    Giacomini P, Imberti L, Azuzzi A, et al (1985) Immunochemical analysis of the modulation of human melanoma-associated antigens by DNA recombinant immune interferon. J Immunol 135: 2887–2893PubMedGoogle Scholar
  94. 93.
    Murray JL, Stuckey SE, Pillow JK, et al (1988) Differential in vitro effects of recombinant a-interferon and recombinant y-interferon alone or in combination on the expression of melanoma-associated surface antigen. J Biol Resp Mod 7: 152–169Google Scholar
  95. 94.
    Murray JL, Rosenblum MG, Lamki LM, et al (1986) Enhancement of tumor uptake of 111 indium (111In)-labeled anti-melanoma monoclonal antibody (MoAb) 96.5 in melanoma patients receiving partially purified alpha interferon ( IFN-a ). Proc Amer Soc Clin Oncol 5: 226Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • M. Micksche

There are no affiliations available

Personalised recommendations